Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Investor Presentation (February 2015)
18 slides from Ani Pharmaceuticals's investor presentation, Feb 27, 2015
Slide 1: A Specialty Pharmaceutical Company: Corporate Presentation February 2015
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation February 2015
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, stat
Slide 3: ANI Mission Statement
3 3 ANI Mission Statement ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. ANI’s mission is to develop, manufacture, and market niche generic pharmaceuticals, focusing on opportunities in p
Slide 4: ANI Overview – Positioned for Growth
4 ANI Overview – Positioned for Growth ANI Today ▪ Experienced management team ▪ Current business – For the year ended December 31, 2014: $56.0 million total net revenues □ $46.9 million ANI Rx product revenues □ $9.1 million c ontract manufacturing/services revenues □ Growth of 86% year/year ▪ Guid
Slide 5: ANI History and Highlights
5 5 ANI History and Highlights 2010 Management implemented strategy to focus on ANI - labeled Rx products 2011 Expanded marketed Rx portfolio to seven products 2013 Completed merger with BioSante Pharmaceuticals and obtains NASDAQ Global Market listing (NASDAQ: ANIP), June 2013 2013 Announced agreem
Slide 6: Sales and Marketing / Financial Overview
6 6 Sales and Marketing / Financial Overview
Slide 7: ANI Historical Revenue Growth
7 ANI Historical Revenue Growth 7 $s in millions 39% C ost of sales as a percentage of net revenues, excluding depreciation and amortization 42% 43% 33% 21%
Slide 8: ANI Current Rx Product Portfolio
8 ANI Current Rx Product Portfolio Generic Products Position Market Share (1) EE/MT Tablets #1 44% Fluvoxamine Tablets #1 55% HC Enema #1 90% Metoclopramide Solution #2 29% Opium Tincture #1 73% Methazolamide Tablets Launched November 2014 8 Branded Products Lithobid ® Vancocin ® C ortenema ® Reglan
Slide 9: ANI Contract Manufacturing Revenues
9 ANI Contract Manufacturing Revenues 9 Current Business ▪ $9.1 million in contract manufacturing and services revenues during the year ended December 31, 2014 ▪ Four customers – Eight products and nineteen SKUs Future Opportunities ▪ Potential future royalty: Teva’s testosterone gel
Slide 10: ANI Financial Highlights
10 ANI Financial Highlights 10 2014 Results ($ in millions) Year ended Dec 31, 2014 Dec 31, 2013 % Growth Net revenues $56.0 $30.1 86% Adjusted non - GAAP EBITDA (1) $27.3 $7.5 264% (1) Please see page 18 for US GAAP reconciliation (2) February 19, 2015 press release Annual Guidance – 2015 (2) ($ in
Slide 11: Product Development / Business Development Overview
11 11 Product Development / Business Development Overview
Slide 12: ANI Product Development Pipeline
12 12 ANI Product Development Pipeline Development Pipeline: 46 p roducts in development ▪ Nine filed products – One ANDA granted expedited review – Development collaborations: Ricon, Sofgen, Sterling ▪ Total combined current market: $3.0 billion (1) (1) Based on Company estimates, and recent IMS an
Slide 13: ANI Business Development Highlights
13 13 ANI Business Development Highlights Acquired Vancocin ® and related assets, August 2014 Acquired Lithobid ® , July 2014 Acquired 31 generic products, December 2013 Product development partnership with Sofgen, August 2013; expanded, April 2014 Product development partnership with Ricon, June 20
Slide 14: Manufacturing Overview
14 14 Manufacturing Overview
Slide 15: ANI Manufacturing – Main Street Facility
15 15 ANI Manufacturing – Main Street Facility Location: Baudette , Minnesota ▪ 52,000 square feet of manufacturing , packaging, and warehouse facilities ▪ Rx solutions , suspensions , topicals , tablets , and capsules ▪ DEA - licensed for Schedule II controlled substances ▪ 17,000 square feet of la
Slide 16: ANI Manufacturing – IDC Road Facility
16 16 ANI Manufacturing – IDC Road Facility Location: Baudette, Minnesota ▪ Fully - contained h igh potency facility with capabilities to manufacture h ormone , steroid , and oncolytic products ▪ 47,000 square feet of manufacturing and packaging, and warehouse facilities ▪ 100 nano - gram per eight
Slide 17: ANI Summary
17 ANI Summary ANI is an integrated specialty generic pharmaceutical firm with: ▪ Profitable base business generating organic growth – 2015 Annual guidance (1) □ Net revenues of $80 million to $88 million □ Adjusted non - GAAP EBITDA of $48.8 million to $53.1 million □ Adjusted non - GAAP EPS of $2.
Slide 18: U.S. GAAP Reconciliations
18 U.S. GAAP Reconciliations 18 2014 2013 Operating Income $20,006 $898 Add back Depreciation and amortization 3,878 1,110 Add back Stock-based compensation 3,423 36 Merger-related expenses, not already added back Adjusted EBITDA $27,307 $7,512 5,468 - ANI Pharmaceuticals, Inc. and Subsidiary Adjust
ANI Pharmaceuticals — Investor Presentation (February 2015) on 6ix